Biomarker for differential diagnosis of severe pulmonary tuberculosis
By detecting the content of xanthine oxidase (XO) in the patient's blood, it solves the problem that it is difficult to diagnose severe pulmonary tuberculosis early in the prior art, provides an efficient differential diagnosis method, and improves the prognosis and treatment effect of patients.
Patent Information
- Application Number
- CN202411213153.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-30
AI Technical Summary
The prior art is difficult to accurately diagnose and early warning patients with severe tuberculosis in the early stage, resulting in delayed diagnosis and lag in treatment, affecting the patient's prognosis.
Using xanthine oxidase (XO) as a biomarker, differentiate between severe and non-severe tuberculosis patients by detecting XO content in patients' blood, providing reagents and kits for differential diagnosis, including ELISA and colloidal gold detection kits. Direct, indirect, double anti-sandwich and competition methods are used for testing.
Early identification of patients with severe tuberculosis was achieved, and the area under the ROC curve reached 0.898-0.904, providing a basis for early evaluation and intervention, and improving the treatment effect of patients.
Smart Images

Figure BDA0005020783280000041 
Figure BDA0005020783280000051 
Figure BDA0005020783280000052
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and in particular relates to a biomarker for differential diagnosis of severe pulmonary tuberculosis. Background Art
[0002] Tuberculosis (TB) is a chronic granulomatous inflammation caused by infection with Mycobacterium tuberculosis (MTB), and pulmonary tuberculosis (PTB) is the most common. According to the World Health Organization, about one-third of the world's population has been invaded by Mycobacterium tuberculosis. After Mycobacterium tuberculosis invades lung tissue, inflammatory cells aggregate and release a large number of pro-inflammatory factors, activating effector cells such as multinuclear leukocytes, alveolar macrophages and endoglins, releasing a large number of oxygen free radicals, inducing lipid peroxidation, leading to alveolar epithelial damage, capillary leakage, digestion of antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPX), and increased malondialdehyde (MDA). Therefore, there is an imbalance between oxidation and antioxidant in pulmonary tuberculosis. Antioxidant therapy is beneficial to the recovery of tuberculosis patients in the comprehensive treatment of tuberculosis. At present, pulmonary tuberculosis patients are mainly treated with drugs in clinical practice.
[0003] Due to delayed diagnosis, dialysis, HIV infection or immunosuppression, and multidrug-resistant diseases, patients may develop more severe forms of the disease and require treatment in an intensive care unit. The most common indications for TB-related admission to the intensive care unit (ICU) are acute respiratory failure caused by pneumonia or acute respiratory distress syndrome (ARDS). ARDS is a rare phenomenon in PTB, but it is the most common reason for TB patients to be admitted to the ICU. Approximately 3.4% of hospitalized tuberculosis patients require ICU admission. Compared with severe pneumonia caused by other reasons, patients who require ICU admission have a poor prognosis and a high mortality rate (60 vs 25%) (CHAUDHRYD, TYAGID. Tuberculosis in Intensive Care Unit[J]. Indian J Crit Care Med, 2021, 25(Suppl 2):S150-S4.). Literature reports that the mortality rate of pulmonary tuberculosis patients depends on the severity of the disease. Early warning, timely diagnosis and targeted treatment of severe pulmonary tuberculosis patients directly affect the mortality rate of patients (Chen Hongmei, Wu Xiaoguang, Ma Liping, et al. Analysis of clinical characteristics of 163 elderly patients with tuberculosis who died in hospital [J]. Chinese Journal of Anti-Tuberculosis, 2014, 36(01):55-8.). Domestic and foreign research on TB mainly focuses on disease susceptibility, early diagnosis, differential diagnosis, etc., and there are few studies on the progression of pulmonary tuberculosis. Early judgment of the patient's condition and formulation of effective prevention and treatment measures are of clinical significance in reducing the patient's mortality rate.
[0004] Similar to other lung diseases, oxidation and antioxidant imbalance plays a key role in the development of pulmonary tuberculosis (Liang Qingtao, Li Qi, Gu Shuxiang, et al. Effect of N-acetylcysteine adjuvant therapy on oxidation / antioxidant imbalance in patients with pulmonary tuberculosis [J]. Journal of Clinical Pulmonary Medicine, 2013, 18(2): 306-307.). Xanthine oxidase (XO) is a key enzyme in the human body that catalyzes the production of uric acid from xanthine and hypoxanthine. It is also an enzyme that induces stress and is the source of host inflammation. While catalyzing the production of uric acid, it also catalyzes the production of reactive oxygen species (ROS) (DOEHNERW, LANDMESSERU. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options [J]. Semin Nephrol, 2011, 31 (5): 433-40.), and ROS plays an important role in combating various intracellular pathogens (MILKOVIC L, CIPAK GASPAROVIC A, CINDRIC M, et al. Short Overview of ROS as Cell Function Regulators and Their Implications in Therapy Concepts [J]. Cells, 2019, 8 (8).). XO expression is regulated by multiple factors, including hormones, growth factors, inflammatory cytokines, etc. Studies have shown that XO levels in malaria patients are elevated and are associated with inflammatory responses (TY MC, ZUNIGA M, A, et al. Malaria inflammation by xanthine oxidase-produced reactive oxygen species [J]. EMBO MolMed, 2019, 11(8): e9903.). There is currently no report on the role of XO in the progression of PTB. Summary of the invention
[0005] The present invention has been completed based on the discovery that the XO content in the blood of patients with severe pulmonary tuberculosis is significantly lower than that of non-severe subjects.
[0006] In a first aspect, the present invention provides a biomarker for differential diagnosis of severe pulmonary tuberculosis patients, wherein the biomarker is xanthine oxidase (XO). When the content of XO in a patient's biological sample is significantly lower than that in a non-severe sample, the patient is a severe pulmonary tuberculosis patient.
[0007] Furthermore, the biological sample of the patient is selected from blood.
[0008] Preferably, the biological sample of the patient is at least one of peripheral blood, plasma and serum.
[0009] In a second aspect, the present invention provides an application of a biomarker in the preparation of a reagent for differential diagnosis of severe pulmonary tuberculosis patients, wherein the biomarker is XO, and the reagent is a reagent that can detect XO; when the content of XO in the patient's blood is significantly lower than that in non-severe samples, the patient is a severe pulmonary tuberculosis patient.
[0010] Furthermore, the biological sample of the patient is selected from blood.
[0011] Preferably, the biological sample of the patient is at least one of peripheral blood, plasma and serum.
[0012] In a third aspect, the present invention provides a kit for predicting severe pulmonary tuberculosis patients, the kit containing a reagent for detecting the XO content, and when the XO content in the patient's biological sample is significantly lower than that in the non-severe sample, the patient is a severe pulmonary tuberculosis patient.
[0013] Furthermore, the biological sample of the patient is selected from blood.
[0014] Preferably, the biological sample of the patient is at least one of peripheral blood, plasma and serum.
[0015] Furthermore, the kit may be an ELISA detection kit and / or a colloidal gold detection kit.
[0016] Furthermore, the diagnostic method of the kit includes a direct method, an indirect method, a double antibody sandwich method and / or a competitive method.
[0017] Beneficial Effects
[0018] The present invention found that the XO content in the blood of patients with severe pulmonary tuberculosis was significantly lower than that of non-severe subjects, and the area under the ROC curve (AUC) in the screening test was 0.898; the area under the ROC curve (AUC) in the validation test was 0.904. It is helpful to evaluate the condition of patients with pulmonary tuberculosis early, especially to provide a basis for early intervention and comprehensive treatment of severe patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Figure 2 shows the expression level and ROC curve of XO in peripheral blood mononuclear cells of patients with NSTB and STB; (A) shows the expression level of XO in peripheral blood mononuclear cells of 30 patients with NSTB and STB; (B) shows the ROC curve of the expression level in peripheral blood mononuclear cells of 30 patients with NSTB and STB; (C) shows the expression level of XO in peripheral blood mononuclear cells of 15 patients with NSTB and STB; (D) shows the ROC curve of the expression level in peripheral blood mononuclear cells of 15 patients with NSTB and STB. DETAILED DESCRIPTION
[0020] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.
[0021] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.
[0022] Example 1 Study Subject Inclusion Criteria
[0023] Patients who visited Beijing Chest Hospital affiliated to Capital Medical University and were clearly diagnosed with pulmonary tuberculosis from February 2024 to June 2024 were divided into severe group and non-severe group. Patients with pulmonary tuberculosis were included in the severe group if any one of the following four conditions was met: (1) oxygen saturation ≤93% when breathing air at rest; (2) oxygenation index (arterial oxygen partial pressure / oxygen concentration) ≤300 mmHg, or arterial oxygen partial pressure ≤60 mmHg when breathing air at rest; (3) chest imaging showed that the cumulative range of bilateral tuberculosis lesions exceeded 1 / 2 of the entire lung; (4) patients who met the above-mentioned conditions for severe patients but developed shock or combined with other organ failure and required ICU monitoring and treatment, and those who did not meet the above-mentioned severe patient grouping criteria during the same period were all included in the non-severe patient group.
[0024] All patients included in the experiment met the above inclusion criteria.
[0025] Experimental set: According to the above criteria, 30 patients with severe tuberculosis (STB) and non-severe tuberculosis (NSTB) were collected, and the included patients were matched by age and gender.
[0026] Validation set: According to the above criteria, 15 patients with severe tuberculosis (STB) and 15 patients with non-severe tuberculosis (NSTB) were collected, and all included patients were matched by age and gender.
[0027] Example 2 Test method
[0028] 2.1 Blood sample collection and processing
[0029] (1) Collect 10 ml of peripheral blood from the subjects using EDTA anticoagulated vacuum blood collection tubes;
[0030] (2) Add human peripheral blood lymphocyte separation solution (TBD) of equal volume to the blood sample, mix well and centrifuge;
[0031] (3) After centrifugation, transfer the second white cell layer to a new centrifuge tube, add PBS and centrifuge;
[0032] (4) After centrifugation, discard the supernatant, add red blood cell lysis buffer to resuspend the cells, lyse, add buffer to terminate lysis, and centrifuge;
[0033] (5) The supernatant was discarded and the obtained cells were added to FreeZol Reagent for subsequent RNA extraction.
[0034] 2.2 RNA extraction
[0035] 1) Extract total RNA from peripheral blood mononuclear cells, mix the cells with FreeZol Reagent and let stand;
[0036] 2) Add Dilution Buffer, mix well, let stand, and centrifuge;
[0037] 3) Aspirate the supernatant, add isopropanol, mix well, let stand, and centrifuge;
[0038] 4) Discard the supernatant, add ethanol, resuspend the precipitate, centrifuge; repeat the operation, dry, and resuspend the RNA precipitate;
[0039] 5) RNA sample concentration determination: the total RNA concentration and A260 / 280 ratio of all samples were measured using a UV spectrophotometer;
[0041] 6) In this study, RNA samples with an A260 / 280 ratio of about 2 were selected for subsequent experiments, and subsequent experiments were performed when all samples met the criteria.
[0042] 2.3 Reverse transcription and cDNA synthesis
[0043] Reverse transcription was performed using the Hifar II First-Strand cDNA Synthesis Kit (Yesen), with a total system of 20 μL, and the configuration method was as follows:
[0044] Table 1. Reverse transcription system preparation
[0045]
[0046] After the reaction system is prepared, mix it evenly, and react it on a PCR instrument according to the conditions shown in Table 2. After completion, freeze the cDNA sample synthesized by reverse transcription.
[0047] Table 2. Reverse transcription program settings
[0048]
[0049] 2.4 RT-qPCR
[0050] 2.4.1 Primer design and synthesis
[0051] The primer sequences of human GAPDH and differentially expressed genes were searched on the Primer Bank website and verified by Primer-Blast on the NCBI website. The primers were synthesized by Beijing Ruibo Biotechnology Co., Ltd. The primer sequences are shown in Table 3.
[0052] Table 3. Primer sequences
[0053]
[0054] 2.4.2 RT-qPCR detection of mRNA expression levels of each gene
[0055] (1) Adoption The expression levels of each gene to be tested in the two groups were detected by qPCR SYBR green master mix (Low Rox) kit;
[0056] (2) Add each sample to the corresponding 96-well PCR reaction plate according to the reaction system shown in Table 4 below for detection;
[0058] Table 4. RT-qPCR reaction system
[0059]
[0060] (3) Performing the reaction on a PCR system under the following conditions: 95°C for 5 min; 95°C for 10 s and 60°C for 30 s;
[0061] (4) The internal reference is GADPH, and the relative expression level of the gene is based on 2 -ΔΔCt Method normalization.
[0062] 2.5 Data processing and statistical analysis
[0063] The experimental results were statistically analyzed using GraphPad Prism 8 software. Unpaired T-test was used to analyze the differences between groups, and statistical differences were considered significant when P value < 0.05, and asterisks indicate the degree of significance (****, P < 0.0001).
[0064] Example 3 Test results
[0065] 3.1 Screening test
[0066] Blood samples from 30 STB patients and 30 NSTB patients were collected clinically, and peripheral blood mononuclear cells were isolated. Total RNA was extracted for reverse transcription and RT-qPCR. It was found that the XO level in STB patients was reduced ( Figure 1 A), the area under the ROC curve (AUC) was 0.898 ( Figure 1 B).
[0067] 3.2 Verification test
[0068] According to the inclusion criteria, 15 STB and 15 NSTB patients were enrolled, and the expression of XO in peripheral blood mononuclear cells was detected according to the above steps. The results showed that the expression of XO in STB patients was lower, which was consistent with the previous results ( Figure 1 C), and the AUC was 0.904 ( Figure 1 D), has higher prediction performance.
[0069] Therefore, XO can be used as a biomarker for differential diagnosis of PTB patients.
Claims
1. A biomarker for differential diagnosis of severe pulmonary tuberculosis patients, wherein the biomarker is xanthine oxidase (XO). When the content of XO in a patient's biological sample is significantly reduced, the patient is a severe pulmonary tuberculosis patient.
2. Use of a biomarker in the preparation of a reagent for differential diagnosis of severe pulmonary tuberculosis patients, wherein the biomarker is XO, and the reagent is a reagent that can detect XO; when the content of XO in the patient's blood is significantly increased, the patient is a severe pulmonary tuberculosis patient.
3. A kit for predicting severe pulmonary tuberculosis patients, the kit containing a reagent for detecting XO content. When the XO content in a patient's biological sample is significantly increased, the patient is a severe pulmonary tuberculosis patient.
4. The biological sample of the patient according to any one of claims 1 to 3 is selected from blood.
5. The biological sample of the patient according to any one of claims 1 to 3 is at least one of peripheral blood, plasma and serum.
6. The kit as claimed in claim 3 can be an ELISA detection kit and / or a colloidal gold detection kit.
7. The diagnostic method of the kit as claimed in claim 3 comprises direct method, indirect method, double antibody sandwich method and / or competitive method.
Citation Information
Patent Citations
Circulating biomarkers
CN103492590A
Methods for diagnosis of tuberculosis
CN108368551A
Medicine for preventing and / or treating lung disturbance
JP2004131402A
Salivary biomarker for use in the diagnosis, differentiation and neuropsychological evaluation of stroke patients
WO2023170526A1
